Neuroprotective effects of erigeron breviscapus (vant.) hand -mazz on glaucoma-A multi -center clinical trial

作者：Wang, Ning-Li^*; Sun, Xing-Huai; Li, Jing-Zhen; Wang, Jing-Hua; Chen, Xiao-Ming; Lin, Ding; Lue, Jian-Hua; Zhong, Yi-Sheng; Zhang, Chun; Guo, Wen-Yi

来源：International Journal of Ophthalmology, 2008, 1(3): 247-252.

• erigeron breviscapus (vant.) hand-mazz
• glaucoma
• neuroprotection

AIM: To evaluate the neuroprotective effects of a Chinese herbal drug, erigeron breviscapus (vant.) hand-mazz (EBHM), on glaucoma patients with controlled intraocular pressure (TOP) after surgical and/or medical therapies. @@@ METHODS: A total of 99 primary glaucoma patients (113 eyes) with medically or surgically controlled IOP were given orally either EBHM or placebo for 6 months and then evaluated in a multi-center, prospective, randomized and double masked clinical trial by quantifying the visual field changes using visual field defect scoring (VFDS). @@@ RESULTS: After 2, 4, 6 months of treatment, the VFDS in EBHM Group (66 eyes/55 patients) decreased by 0.44+/-1.60, 1.27+/-2.16 and 1.42+/-2.37 respectively, indicating a time-dependent improvement of visual field upon EBHM treatment, whereas the VFDS in Placebo Control Group (47 eyes/47 patients) decreased by -0.02+/-1.5, 0.68+/-1.73 and 0.40+/-1.57 respectively. Statistically, the differences of VFDS between the two groups were significant (P<0.05) at 2 and 4 months, and highly significant at 6 months of treatment (P= 0.007). The average IOP in both groups was 15mmHg (range 8-18mmHg) during the period of the study (P>0.05). No serious side effects were reported in glaucoma patients on EBHM. @@@ CONCLUSION: EBHM appeared to be safe and effective in neuroprotection for patients with glaucoma. More studies are needed to determine the safety and effectiveness of longer-term EBHM treatment.

• 出版日期2008-9-18
• 单位北京大学; 复旦大学; 青岛大学; 中国医学科学院北京协和医院; 上海市闵行区中心医院